XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1

Revenues (Tables)

6 Months Ended

Jun. 30, 2024

Revenues [Abstract]

Schedule of net product revenues by product

The Company’s net revenues consisted of the following for the three and six months ended June 30, 2024 and 2023:

			Three months ended June 30,												Six months ended June 30,
			2024						2023						2024						2023
Products:
Kristalose			$	4,107,834					$	4,110,718					$	7,303,444					$	8,425,846
Sancuso			2,188,776						1,916,966						4,016,544						3,803,759
Vibativ			2,454,481						2,147,826						4,059,970						3,996,013
Caldolor			844,248						1,226,314						2,314,947						2,161,356
Acetadote			43,396						150,163						123,599						320,019
Vaprisol			(941)						8,062						(2,556)						5,544
Omeclamox-Pak			(1,581)						23,857						7,081						39,866
RediTrex			(1,156)						9,493						34,400						(131,552)
Other revenue			213,792						1,295,478						489,121						1,492,664
Total net revenues			$	9,848,849					$	10,888,877					$	18,346,550					$	20,113,515

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration